Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1986 2
1987 1
1988 1
1990 1
1991 3
1992 2
1993 1
1994 2
1995 1
1996 4
1997 6
1998 3
1999 11
2000 5
2001 16
2002 11
2003 9
2004 20
2005 22
2006 28
2007 22
2008 21
2009 12
2010 18
2011 28
2012 23
2013 28
2014 44
2015 46
2016 36
2017 38
2018 32
2019 54
2020 75
2021 67
2022 85
2023 75
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

801 results

Results by year

Filters applied: . Clear all
Page 1
APOC3 siRNA and ASO therapy for dyslipidemia.
Chebli J, Larouche M, Gaudet D. Chebli J, et al. Curr Opin Endocrinol Diabetes Obes. 2024 Apr 1;31(2):70-77. doi: 10.1097/MED.0000000000000857. Epub 2024 Feb 9. Curr Opin Endocrinol Diabetes Obes. 2024. PMID: 38334488 Review.
PURPOSE OF REVIEW: The aim of this review is to present the clinical indications of apolipoprotein C-III (apoC3) inhibition in the therapeutic arsenal for the treatment of lipid disorders and associated risks and to compare the most advanced modalities of apoC3 inhi …
PURPOSE OF REVIEW: The aim of this review is to present the clinical indications of apolipoprotein C-III (apoC3) inhibition in the th …
APOC3 Interference for Familial Chylomicronaemia Syndrome.
Hegele RA. Hegele RA. touchREV Endocrinol. 2022 Nov;18(2):82-83. doi: 10.17925/EE.2022.18.2.82. Epub 2022 Nov 2. touchREV Endocrinol. 2022. PMID: 36694895 Free PMC article.
To reduce the risk of potentially fatal pancreatitis, the management of FCS relies principally on a strict low-fat diet, which is difficult to follow and compromises quality of life. Targeted reduction of apolipoprotein C-III using new anti-APOC3 agents, such as the short …
To reduce the risk of potentially fatal pancreatitis, the management of FCS relies principally on a strict low-fat diet, which is difficult …
ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression.
Zhou J, Mo H, Feng Q, Li L, La J. Zhou J, et al. J Ovarian Res. 2023 Sep 9;16(1):188. doi: 10.1186/s13048-023-01263-6. J Ovarian Res. 2023. PMID: 37689737 Free PMC article.
OBJECTIVE: Aimed to investigate ApoC3 expression in ovary of PCOS, and to discuss its potential role in PCOS progression. ...The relation of ApoC3 and sex hormones was analyzed in mouse plasma. Additionally, the dynamic changes of ApoC3 level in ovaries of he …
OBJECTIVE: Aimed to investigate ApoC3 expression in ovary of PCOS, and to discuss its potential role in PCOS progression. ...The rela …
Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3).
Ginsberg HN, Goldberg IJ. Ginsberg HN, et al. Arterioscler Thromb Vasc Biol. 2023 Mar;43(3):388-398. doi: 10.1161/ATVBAHA.122.317966. Epub 2022 Dec 29. Arterioscler Thromb Vasc Biol. 2023. PMID: 36579649 Free PMC article. Review.
The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 (apolipoprotein C3) and ANGPTL (angiopoietin-like protein) 3 that reduce circulati …
The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Dri …
Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I, Schwarz J, Berthold HK. Gouni-Berthold I, et al. Curr Atheroscler Rep. 2023 Oct;25(10):701-709. doi: 10.1007/s11883-023-01140-z. Epub 2023 Aug 29. Curr Atheroscler Rep. 2023. PMID: 37642858 Free PMC article. Review.
The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. Olezarsen, an N-acetylgalactosamine (GalNAc)-conjugated ASO with the same target, seems to have a better safety and efficacy profile. siRNA target …
The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. Olezar …
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
Prohaska TA, Alexander VJ, Karwatowska-Prokopczuk E, Tami J, Xia S, Witztum JL, Tsimikas S. Prohaska TA, et al. J Clin Lipidol. 2023 May-Jun;17(3):406-411. doi: 10.1016/j.jacl.2023.04.007. Epub 2023 Apr 27. J Clin Lipidol. 2023. PMID: 37164837 Free article.
We studied the effect of volanesorsen, a potent antisense oligonucleotide targeting APOC3 mRNA, on hepatic fat fraction (HFF) assessed by MRI in patients with severe hypertriglyceridemia (SHTG, triglycerides 500 mg/dL), familial partial lipodystrophy (FPL, triglycerides 20 …
We studied the effect of volanesorsen, a potent antisense oligonucleotide targeting APOC3 mRNA, on hepatic fat fraction (HFF) assesse …
New Trends in Dyslipidemia Treatment.
Jang AY, Lim S, Jo SH, Han SH, Koh KK. Jang AY, et al. Circ J. 2021 May 25;85(6):759-768. doi: 10.1253/circj.CJ-20-1037. Epub 2020 Nov 12. Circ J. 2021. PMID: 33177309 Free article. Review.
ASOs targeting TG/TRL, such as angiopoietin-like 3 or 4 (ANGPTL3 or ANGPTL4), apolipoprotein C-III (APOC3), or Lp(a) have effectively lowered the corresponding lipid profiles without requiring high or frequent doses. ...
ASOs targeting TG/TRL, such as angiopoietin-like 3 or 4 (ANGPTL3 or ANGPTL4), apolipoprotein C-III (APOC3), or Lp(a) have effectively …
Addressing dyslipidemic risk beyond LDL-cholesterol.
Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Tall AR, et al. J Clin Invest. 2022 Jan 4;132(1):e148559. doi: 10.1172/JCI148559. J Clin Invest. 2022. PMID: 34981790 Free PMC article. Review.
Rare genetic variants that lower triglyceride levels via activation of lipolysis and associate with reduced CVD suggest new approaches to treating dyslipidemia. Apolipoprotein C3 (APOC3) and angiopoietin-like 3 (ANGPTL3) have emerged as targets for inhibition by antibody, …
Rare genetic variants that lower triglyceride levels via activation of lipolysis and associate with reduced CVD suggest new approaches to tr …
Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization Study.
Yu Z, Zhang L, Zhang G, Xia K, Yang Q, Huang T, Fan D. Yu Z, et al. Ann Neurol. 2022 Sep;92(3):390-399. doi: 10.1002/ana.26426. Epub 2022 Jun 24. Ann Neurol. 2022. PMID: 35655417
METHODS: Two-sample Mendelian randomization (MR) analyses were conducted to evaluate the associations of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein (Apo)B and ApoA1 levels with risks for ICH, and those of …
METHODS: Two-sample Mendelian randomization (MR) analyses were conducted to evaluate the associations of high-density lipoprotein cholestero …
801 results